Stock 688321 SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Shenzhen Chipscreen Biosciences Co., Ltd. Stock

Equities

688321

CNE100003LW0

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-05 pm EDT 		5-day change 1st Jan Change
23.05 CNY +5.20% Intraday chart for Shenzhen Chipscreen Biosciences Co., Ltd. +5.78% +5.01%
Apr. 30 National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma CI
Apr. 28 Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 705M 97.7M Sales 2025 * 938M 130M Capitalization 9.62B 1.33B
Net income 2024 * -160M -22.17M Net income 2025 * -77M -10.67M EV / Sales 2024 * 13.6 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 10.3 x
P/E ratio 2024 *
-59.1 x
P/E ratio 2025 *
-121 x
Employees 1,057
Yield 2024 *
-
Yield 2025 *
-
Free-Float 61.29%
More Fundamentals * Assessed data

Chart Shenzhen Chipscreen Biosciences Co., Ltd.

Dynamic Chart

Latest news about Shenzhen Chipscreen Biosciences Co., Ltd.

National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders MT
Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024. CI
Shenzhen Chipscreen Biosciences Co., Ltd. commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024. CI
Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chipscreen Biosciences' New Production Line Passes Regulatory Inspection MT
Chipscreen Biosciences Gets Regulatory Nod for China Clinical Trial of Psoriasis Drug MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shenzhen Chipscreen Biosciences Co., Ltd.(XSSC:688321) added to S&P Global BMI Index CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chinese Drug Regulator to Prioritize Shenzhen Chipscreen Biosciences' Application for Chidamide Tablets MT
Shenzhen Chipscreen Biosciences Gets Nod for Tumor Drug Trial MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news

Analyst Recommendations on Shenzhen Chipscreen Biosciences Co., Ltd.

Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders MT
More recommendations

Press releases Shenzhen Chipscreen Biosciences Co., Ltd.

Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008 AQ
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008 BU
More press releases

News in other languages on Shenzhen Chipscreen Biosciences Co., Ltd.

Biocytogens Tochtergesellschaft Eucure Biopharma und die Tochtergesellschaft der Holding Chipscreen Biosciences, Chipscreen NewWay Biosciences, schließen einen Lizenzvertrag für die Region China über den bispezifischen Antikörper YH008
More news

Quotes and Performance

1 day+5.20%
1 week+5.78%
Current month+5.20%
1 month+10.13%
3 months+61.19%
6 months-4.75%
Current year+5.01%
More quotes

Highs and lows

1 week
22.10
Extreme 22.1
23.25
1 month
18.96
Extreme 18.96
23.25
Current year
12.47
Extreme 12.47
23.25
1 year
12.47
Extreme 12.47
26.00
3 years
12.47
Extreme 12.47
47.76
5 years
12.47
Extreme 12.47
125.00
10 years
12.47
Extreme 12.47
125.00
More quotes

Managers and Directors - Shenzhen Chipscreen Biosciences Co., Ltd.

Managers TitleAgeSince
Zhi Qiang Ning FOU
 Founder 64 01-03-20
Xian Ping Lu CEO
 Chief Executive Officer 61 01-03-20
Jian Xun Li DFI
 Director of Finance/CFO 53 01-05-31
Members of the board TitleAgeSince
Xian Ping Lu CEO
 Chief Executive Officer 61 01-03-20
Jian Xun Li DFI
 Director of Finance/CFO 53 01-05-31
Rui Lin Song BRD
 Director/Board Member 61 18-06-25
More insiders

ETFs positioned on Shenzhen Chipscreen Biosciences Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 0 M€ +3.63% -
More ETFs positioned on Shenzhen Chipscreen Biosciences Co., Ltd.

Quotes

Date Price Change Volume
24-05-06 23.05 +5.20% 7,203,489
24-04-30 21.91 +0.55% 3,700,439

End-of-day quote Shanghai S.E., May 05, 2024

More quotes

Company Profile

Shenzhen Chipscreen Biosciences Co Ltd is a China-based company mainly engaged in the research and development of original innovative drugs. The Company focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The Company's main products include Chidamide, Siglitazone, Cioroni and CS12192. The Company mainly conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-07-29 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Shenzhen Chipscreen Biosciences Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
23.05 CNY
Average target price
26.33 CNY
Spread / Average Target
+14.23%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. Stock Shenzhen Chipscreen Biosciences Co., Ltd.
+5.01% 1.3B
MERCK KGAA Stock Merck KGaA
+6.49% 71.18B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+13.33% 9.23B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-13.75% 5B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+41.51% 4.46B
YUHAN CORPORATION Stock Yuhan Corporation
+4.51% 3.95B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-15.23% 2.54B
INDIVIOR PLC Stock Indivior PLC
+21.43% 2.44B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-25.12% 2.36B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+19.51% 2.18B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688321 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW